Safety profile of JAK inhibitors in inflammatory or autoimmune diseases

Area of Science:

• Immunology
• Pharmacology
• Rheumatology

Background:

• Janus kinase inhibitors (JAKi) are increasingly used for inflammatory and autoimmune conditions.
• Concerns exist regarding the safety profile of JAK inhibitors, particularly infectious and cardiovascular risks.

Purpose of the Study:

• To review the adverse effects associated with Janus kinase inhibitors.
• To highlight the importance of prevention strategies for JAK inhibitor-related side effects.

Main Methods:

• Literature review of Janus kinase inhibitor adverse events.
• Analysis of risks including infection, malignancy, cardiovascular events, and gastrointestinal perforation.
• Examination of biological abnormalities associated with JAK inhibitor use.

Main Results:

• JAK inhibitors are associated with increased risks of infection, malignancy, venous thromboembolism, and major cardiovascular events.
• Certain patient groups, including older adults, smokers, and those with risk factors, are at higher risk for adverse events.
• Biological abnormalities like cytopenias, dyslipidemia, and elevated CPK levels are also noted.

Conclusions:

• Effective prevention strategies, including screening, vaccination, and prophylaxis, are crucial for mitigating JAK inhibitor risks.
• Risk stratification and monitoring are essential for identifying and managing patients at higher risk of adverse events.
• Understanding and managing the side effect profile of JAK inhibitors is vital for optimizing patient outcomes.